Additionally, the Huda research group utilized monoclonal antibody (mAb)–small interfering RNA (siRNA) conjugates targeting the B cell activating factor receptor (BAFF receptor) or B cell maturation antigen (BCMA) receptor, successfully improving clinical symptoms in patients with myasthenia gravis (MG) [73,74]. This evidence concerns the gene TNFRSF17 and myasthenia gravis.